Skip to content

Other product segments

Financial
23%+82.5%
Casualty
22.2%-7.5%
Property
3%+7.1%
Multiline
1.6%0.0%
Health
0%

Similar metrics at other companies

Arch Capital Group logo
ACGLSpecialty — Year Five
5.4%+0.2pp
Horace Mann Educators logo
HMNSpecialty Health — Year Five
0%
SiriusPoint logo
SPNTOther Specialties — Year 5
3.4%+1.7pp
Kemper logo
KMPRSpecialty Personal Automobile Insurance—Liability — Year 5
96.8%-0.6pp
White Mountains Insurance Group logo
WTMSpecialty — 5
6.3%-1.0pp
Arch Capital Group logo
ACGLSpecialty — Year Six
3.8%-0.2pp

Other financials

Income statement

See full
Revenue$189.7M-11.1%
Net income$35.8M+20.7%
EPS (diluted)$1.05+22.1%

Balance sheet

See full
Cash & equivalents$610.2M-5.1%
Total debt$4.7M-92.1%
Total equity$741.2M+11.2%
Total assets$2.3B+5.4%

Cash flow

See full
Operating cash flow$37.2M+259%

Valuation

See full
Market cap$533.32M+7.2%
Enterprise value-$72.18M-15.4%
P/E6.6×
P/S0.8×+0.1×

Profitability

See full
Net margin11.5%
FCF margin-46.7%

Returns & leverage

See full
Return on equity11.5%
Debt / equity-0.1×

Where this comes from

Reported directly by Greenlight Capital RE, Ltd. in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearFive.

The official record: Greenlight Capital RE, Ltd.’s 10-K, filed March 9, 2026, on SEC EDGAR. View the filing →

Ask your AI about Greenlight Capital RE, Ltd.'s specialty — year 5.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Greenlight Capital RE, Ltd.'s specialty — year 5?
Greenlight Capital RE, Ltd. (GLRE) reported specialty — year 5 of 17.6% in Q4 2025.
What does specialty — year 5 mean?
This metric represents the specialty segment's underwriting performance or claims development in the fifth year of a policy cohort. It reflects the long-term profitability and final settlement characteristics of the specialty reinsurance portfolio. Analyzing this helps investors understand the historical accuracy of long-term specialty loss projections.